Company Overview and News

 
STRATA Skin Sciences to Participate in Panel Discussion at The MedTech Conference

2018-09-17 globenewswire
HORSHAM, Pa., Sept. 17, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will participate in a panel discussion, titled “Alternative to the Exit: Start-ups building long-term value” at The MedTech Conference at the Pennsylvania Convention Center in Philadelphia on Monday, September 24th at 8:30 am Eastern Time.
MELA SSKN

21
Week 38 Breakout Forecast: Short-Term Picks To Give You An Edge

2018-09-17 seekingalpha - 4
Publishing two of the eight new Week 38 breakout stocks that are available only to subscribers, with better than 10% short-term upside potential.
ADAP EVC CGEN SW SSKN MEIP SWIR CDMO MELA MNOV CMCM PXLW GOGO

3
Strata Skin Sciences: Will This Be A Successful Turnaround In The Making?

2018-09-07 seekingalpha - 3
The management is streamlining with the appointment of the interim CEO (Dr. Dolev Rafaeli) is prudent.
MELA SSKN

 
STRATA Skin Sciences to Participate in H.C. Wainwright’s 20th Annual Global Investment Conference

2018-08-27 globenewswire
HORSHAM, Pa., Aug. 27, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will present a corporate overview at the H. C.
MELA SSKN

 
STRATA Skin Sciences Announces Strategic Agreement with a Large Private Equity Backed Group of Dermatology Clinics

2018-08-20 globenewswire
Agreement will add to group’s business offering and enhance the individual clinics’ abilities to offer proven and cost-effective treatments to psoriasis, vitiligo and atopic dermatitis patients
MELA SSKN

 
STRATA Skin Sciences, Inc. (SSKN) CEO Dr. Dolev Rafaeli on Q2 2018 Results - Earnings Call Transcript

2018-08-13 seekingalpha
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q2 2018 Results Earnings Conference Call August 13, 2018 4:30 PM ET
MELA SSKN

30
Your Daily Pharma Scoop: Foundation Promising, Paratek Moves Up, Ovid Down

2018-08-08 seekingalpha - 2
Discussion: Foundation Medicine’s (FMI) announced a positive outcome of its bTMB assay. In a recent publication in Nature Medicine, a retrospective analysis of more than one thousand samples from NSCLC patients who participated in Roche (OTCQX:RHHBY) Genetech’s trials showed that use of Foundation Medicine’s (FMI) blood tumor mutational burden (‘bTMB) assay would have helped predict responses to TECENTRIQ (atezolizumab).
INO GILD PRTK TEVA OVID TEVVF ELTP SSKN PTIE MELA TEVJF EIGR PTGX FMI PFE

 
STRATA Skin Sciences Announces FDA Granted 510(k) Clearance for the Multi Micro Dose™ Tip for its XTRAC® 308nm Excimer Laser

2018-08-06 globenewswire
MMD Tip Offers Faster Patient Outcomes at Uncompromised Safety, Higher Patient Retention and Lower Costs for Patient and Payer
MELA SSKN

6
Top 10 Stocks Under $20

2018-07-25 zacks - 2
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive”, and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
LMT RUN CFCO CFCOW SSKN BP CFCOU BP.A BP.B GRPN MELA BP BPAQF

 
STRATA Skin Sciences Announces Licensing Agreement for Certain MelaFind Assets

2018-07-23 globenewswire
HORSHAM, Pa., July 23, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ:SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced a fully paid exclusive and perpetual license agreement with a strategic entity for a de-identified digital image library of pigmented lesions and their related documentary information, related to STRATA’s discontinued MelaFind device.
MELA SSKN

1
Is Strata Skin Sciences (SSKN) Outperforming Other Medical Stocks This Year?

2018-07-17 zacks - 1
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Strata Skin Sciences (SSKN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
MELA SSKN

 
Has Strata Skin Sciences (SSKN) Outpaced Other Medical Stocks This Year?

2018-07-17 zacks
Investors focused on the Medical space have likely heard of Strata Skin Sciences (SSKN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of SSKN and the rest of the Medical group's stocks.
MELA SSKN

4
STRATA Skin Sciences Announces 510(k) Submission for its Multi Micro Dose™ Tip Accessory for the XTRAC® 308nm Excimer Laser

2018-06-19 globenewswire
HORSHAM, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ:SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its Multi-Micro Dose™ (“MMD”) tip accessory for the proprietary XTRAC® 308nm excimer laser.
MELA SSKN

4
STRATA Skin Sciences to Participate in Panel Discussion at Cantor Fitzgerald Dermatology & Aesthetics Summit

2018-06-13 globenewswire
HORSHAM, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ:SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will participate in a panel discussion, titled “New Medical Dermatology Treatments Which Target Established Large Markets” at the Cantor Fitzgerald Dermatology & Aesthetics Summit at the Westin Grand Central Hotel in New York on Tuesday, June 19th at 11:00 am Eastern Time.
MELA SSKN

10
STRATA Skin Sciences Announces Closing of a $17 Million Equity Financing and the Formal Appointment of New Management to Accelerate Growth and Enrich its XTRAC® Business Strategy

2018-05-29 globenewswire
HORSHAM, Pa., May 29, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ:SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that its shareholders have voted in favor of an equity financing, raising proceeds of $17 million. The financing was led by Accelmed Growth Partners (“AGP”), a private equity investment firm focused on value creation for medical device companies and technologies, through the establishment of platform companies.
MELA SSKN CGNT

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to SSKN / Strata Skin Sciences, Inc. on message board site Silicon Investor.

wirelessknowledge wirelessknowledge wirelessknowledge
CUSIP: 55277R100